Ann: New data supports ATL1102s broader clinical potential, page-5

Dr George Tachas, Antisense Therapeutics Director of Drug Discovery and Patents said, “The
improvement in two genetically inherited modifiers of loss of ambulation in DMD with ATL1102
treatment over six months is to my knowledge yet to be observed with any marketed drugs or those in
development for boys with DMD. TGF-β is implicated in DMD pathology and is known to stimulate
fibrosis and inhibit muscle regeneration. The changes to TPS-1 and LTBP4 are positive observations as
they support ATL1102 applications in DMD, and other muscle dystrophy opportunities that we have
planned and are underway in our collaboration with the MCRI, and other fibrotic disease areas in need
of better treatments.”